Edition:
United States

Atossa Genetics Inc (ATOS.OQ)

ATOS.OQ on NASDAQ Stock Exchange Capital Market

0.31USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
596,625
52-wk High
$1.85
52-wk Low
$0.28

Summary

Name Age Since Current Position

Steven Quay

64 Chairman of the Board, President, Chief Executive Officer

Kyle Guse

51 2013 Chief Financial Officer, General Counsel, Secretary

Cindy Atha

2015 Vice President of Sales and Marketing

Janet Rea

2015 Vice President - Regulatory Affairs and Quality

Shu-Chih Chen

53 2014 Director

Stephen Galli

68 2011 Independent Director

H. Lawrence Remmel

63 2012 Independent Director

Richard Steinhart

59 2014 Independent Director

Gregory Weaver

61 2013 Independent Director

Scott Gordon

2015 IR Contact Officer

Biographies

Name Description

Steven Quay

Dr. Steven C. Quay, M.D., Ph.D. is Chairman of the Board, President, Chief Executive Officer of Atossa Genetics Inc., since April 2009. Prior to his work at the Company, Dr. Quay served as Chairman of the Board, President and Chief Executive Officer of MDRNA, Inc., a biotechnology company focused on the development and commercialization of RNAi-based therapeutic products, from August 2000 to May 2008, and as its Chief Scientific Officer until November 30, 2008 (MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company Inc. and is currently known as Marina Biotech, Inc.). From December 2008 to April 2009, Dr. Quay was involved in acquiring the Company’s assets and preparing the Company’s business plan. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, is a former faculty member of the Department of Pathology, Stanford University School of Medicine, and is a named inventor on 14 U.S. and foreign patents covering the ForeCYTE Breast Aspirator. Including the patents for the ForeCYTE Breast Aspirator, Dr. Quay is a named inventor on 76 U.S. patents, 108 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the U.S. Food and Drug Administration. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan Medical School. He also received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971.

Kyle Guse

Mr. Kyle Guse Esq., CPA., is Chief Financial Officer, General Counsel, Secretary of Atossa Genetics Inc., since January 4, 2013. His experience includes more than 20 years of counseling life sciences and other rapid growth companies through all aspects of finance, corporate governance, securities laws and commercialization. Mr. Guse has practiced law at several of the largest international law firms, including from January 2012 through January 2013 as a partner at Baker Botts LLP and, prior to that, from October 2007 to January 2012, as a partner at McDermott Will & Emery LLP. Before working at McDermott Will & Emery, Mr. Guse previously served as a partner at Heller Ehrman LLP. Mr. Guse began his career as an accountant at Deloitte & Touche and he is a licensed Certified Public Accountant in the State of California. Mr. Guse earned a B.S. in business administration and an M.B.A. from California State University, Sacramento, and a J.D. from Santa Clara University School of Law.

Cindy Atha

Ms. Cindy Atha is Vice President of Sales and Marketing of Atossa Genetics Inc. Prior to joining Atossa, Ms. Atha was Vice President of Managed Markets for Depomed, leading a team that focused on third party reimbursement, pricing, and distribution management. While Vice President of Managed Markets and Trade at Amylin Pharmaceuticals, her team was twice recognized for "Best Marketing Programs and People" for a small manufacturer, and also achieved the 2012 DIANA Award for best new product introduction. Ms. Atha began her 24 years of pharmaceutical experience in field sales with Merck & Co. and then moved to AstraZeneca where she advanced into senior sales leadership. She has received more than 16 sales awards for exceptional individual and group performance including AstraZeneca's prestigious "Leadership Excellence Award." Ms. Atha helped bring over 15 new pharmaceutical products to market and she gained formative experience as an account executive with scientific technologies, promoting the sale of research and medical equipment to leading biotechnology companies and medical centers. She also serves on the Board of Directors for Operation of Hope, a non-profit organization that provides facial reconstructive surgeries to poor children around the world. Ms. Atha received her Bachelor of Science in Zoology from North Carolina State University in Raleigh, North Carolina.

Janet Rea

Ms. Janet Rose Rea, M.S.P.H., is Vice President - Regulatory Affairs and Quality of Atossa Genetics, Inc. Ms. Rea has nearly 35 years of industry leadership experience in regulatory affairs and quality. A Washington native, she obtained her B.S. degree in Microbiology from the University of Washington and was conferred a Master's of Science of Public Health from the same institution. Her career in the healthcare industry started with Miami, FL-based Dade Division of then American Hospital Supply Corporation (now Baxter), followed by Genetic Systems, and she was an early employee of Seattle-based Immunex Corporation where she played a key role in the company's first licensed product, LEUKINE®. She held positions with increasing levels of responsibility with MDS Pharma, Targeted Genetics, and executive positions with AVI BioPharma (now Sarepta), Poniard Pharmaceuticals and Protein Sciences Corporation (Meriden, CT), and Therapeutic Proteins International (Chicago, IL). She has also operated a consulting practice of both small and large organizations, and she has lectured at both Shoreline Community College and the University of Washington - Biomedical Regulatory Affairs Certificate and Master Program, where she was also appointed as an Assistant Clinical Professor.

Shu-Chih Chen

Dr. Shu-Chih Chen, Ph.D., is Director of Atossa Genetics Inc., effective August 15, 2014. Prior to that .Dr. Chen has served as a director of the Company since April 2009.Prior to joining the Company, Dr. Chen served as President of Ensisheim beginning in 2008, was founder and President of SC2Q Consulting Company from 2006 to 2008, and served as Head, Cell Biology, Nastech Pharmaceutical Company, Inc. from 2002 to 2006. During 1995 and 1996, she was an Associate Professor at National Yang Ming University, Taipei, Taiwan, and served as the principal investigator of an NIH RO1 grant studying tumor suppression by gap junction protein connexin 43 at the Department of Molecular Medicine at Northwest Hospital before working in the research department at Nastech Pharmaceutical Company. She is named as an inventor on four patent applications related to cancer therapeutics. Dr. Chen received her Ph.D. degree in microbiology and public health from Michigan State University in 1992 and has published extensively on Molecular Oncology. She received her B.S. degree in medical technology from National Yang Ming University, Taipei, Taiwan in 1984.

Stephen Galli

Dr. Stephen J. Galli, M.D. is Independent Director of Atossa Genetics Inc., since July 2011. Dr. Galli is Chair of the Department of Pathology, Professor of Pathology and of Microbiology & Immunology and the Mary Hewitt Loveless, M.D., Professor, Stanford University School of Medicine, Stanford, California, and has served in these capacities since February 1999. Before joining Stanford, he was on the faculty of Harvard Medical School. He holds 13 U.S. patents and has over 340 publications. He is past president of the American Society for Investigative Pathology and was president of the Collegium Internationale Allergologicum. From 2010-2014. In addition to receiving awards for his research, he was recently recognized with the 2010 Stanford University President’s Award for Excellence through Diversity for his recruitment and support of women and underrepresented minorities at Stanford University. He received his B.A. degree in biology, magna cum laude, from Harvard College in 1968 and his M.D. degree from Harvard Medical School in 1973 and completed a residency in anatomic pathology at the Massachusetts General Hospital in 1977.

H. Lawrence Remmel

Mr. H. Lawrence Remmel, Esq. is Independent Director of Atossa Genetics Inc., since February 8, 2012. He is currently a partner of the law firm Pryor Cashman LLP, located in New York City, where he chairs the Banking and Finance practice group. Mr. Remmel joined Pryor Cashman in 1988. His practice includes corporate and banking financings, issues relating to the Investment Company Act of 1940, and intellectual property and licensing issues, in particular in the biotechnology and biocosmeceutical areas. Mr. Remmel serves on the Board of Advisors of CytoDel, LLC, an early stage bio-pharmaceutical company developing products for bio defense, neurol drug delivery and aesthetic medicine. He was an associate of the law firm Reboul, MacMurray, Hewitt, Maynard & Kristol from 1984 to 1988, and began his legal career at Carter, Ledyard & Milburn, where he was an associate from 1979 to 1984. He was admitted to the New York bar in 1980 and is a member of the New York State Bar Association. He received his J.D. from the Washington & Lee University School of Law in 1979 and his B.A. from Princeton University in 1975.

Richard Steinhart

Mr. Richard I. Steinhart is Independent Director of the ATOSSA GENETICS INC. Mr. Steinhart was an executive at MELA Sciences, Inc., most recently serving as its Chief Financial Officer, Senior Vice President, Treasurer and Secretary. From 1992 to 2006, Mr. Steinhart was Managing Director at Forest St. Capital/SAE Ventures. Earlier, he served as Vice President and Chief Financial Officer at Emisphere Technologies from 1991 to 1992 and as General Partner and Chief Financial Officer of CW Group Inc. Mr. Steinhart is a Member of the Board of Directors of Actinium Pharmaceuticals where he is Chairman of the Audit Committee and a member of the Compensation Committee. From 2004 to 2012, Mr. Steinhart was a Member of the Board of Directors of Manhattan Pharmaceuticals and was Chairman of the Audit Committee. Mr. Steinhart received his B.B.A. and M.B.A. degrees from Pace University.

Gregory Weaver

Mr. Gregory L. Weaver is Independent Director of Atossa Genetics Inc. Weaver has built a successful career in executive financial and operations management serving as CFO of small to mid-cap public and private biotechnology companies. He currently serves as Global Chief Financial Officer of Oryzon Genomics, an epigenetics company. From August 2013 to October 2014, Mr. Weaver served as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of Fibrocell Science, Inc., an autologous cellular therapeutic company. From June 2011 to July 2013, Mr. Weaver served as Chief Financial Officer and Senior Vice President of Celsion Corp., an oncology drug development company. From February 2009 to August 2010, Mr. Weaver served as Chief Financial Officer and Senior Vice President of Poniard Pharmaceuticals, Inc., a drug development company. From April 2007 to December 2008, Mr. Weaver served as Chief Financial Officer of Talyst, Inc., an information technology services company. Mr. Weaver received his B.S. degree from Trinity University and his M.B.A. degree from Boston College.

Scott Gordon

Basic Compensation